Peptides for the Treatment of HCV Infections
    21.
    发明申请
    Peptides for the Treatment of HCV Infections 审中-公开
    用于治疗HCV感染的肽

    公开(公告)号:US20120244122A1

    公开(公告)日:2012-09-27

    申请号:US13321785

    申请日:2010-05-28

    申请人: Craig E. Masse

    发明人: Craig E. Masse

    摘要: This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are deuterated derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating HCV infection.

    摘要翻译: 本发明涉及作为肽衍生物和其药学上可接受的盐的新化合物。 更具体地,本发明涉及作为波普瑞韦的氘化衍生物的新型肽。 本发明还提供包含一种或多种本发明化合物和载体的组合物,以及所述化合物和组合物在治疗HCV感染的方法中的用途。

    DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES
    22.
    发明申请
    DEUTERATED 2-AMINO-3-HYDROXYPROPANOIC ACID DERIVATIVES 有权
    去除2-氨基-3-羟基丙酸衍生物

    公开(公告)号:US20110251131A1

    公开(公告)日:2011-10-13

    申请号:US13119318

    申请日:2009-09-15

    申请人: Craig E. Masse

    发明人: Craig E. Masse

    摘要: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.

    摘要翻译: 本发明涉及新的2-氨基-3-羟基丙酸衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用NMDA甘氨酸位点拮抗剂有益治疗的疾病和病症的方法中的用途。

    Substituted oxazolidinone derivatives
    23.
    发明授权
    Substituted oxazolidinone derivatives 有权
    取代恶唑烷酮衍生物

    公开(公告)号:US07985750B2

    公开(公告)日:2011-07-26

    申请号:US12228662

    申请日:2008-08-14

    申请人: Craig E. Masse

    发明人: Craig E. Masse

    IPC分类号: A61K31/535 C07D413/14

    CPC分类号: C07D413/14

    摘要: This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban.

    摘要翻译: 本发明涉及取代的恶唑烷酮衍生物的新化合物及其药学上可接受的盐。 更具体地,本发明涉及作为利伐沙班的衍生物的新的恶唑烷酮化合物。 本发明还提供了包含一种或多种本发明化合物和载体的无热原组合物,以及所公开的化合物和组合物在治疗通过施用选择性因子Xa抑制剂有益治疗的疾病和病症的方法中的用途, 作为利伐沙班。

    NOVEL TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES
    24.
    发明申请
    NOVEL TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES 审中-公开
    新四氢-1H-吡咯并[4,3-B]吲哚

    公开(公告)号:US20100137215A1

    公开(公告)日:2010-06-03

    申请号:US12625059

    申请日:2009-11-24

    摘要: This invention relates to novel tetrahydro-1H-pyrido[4,3-b]indoles, their derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by NMDA antagonists, acetylcholinesterase inhibitors, 5-HT6 antagonists, other neuroprotectors, antihistamines and agents that delay age-related pathologies and conditions.

    摘要翻译: 本发明涉及新的四氢-1H-吡啶并[4,3-b]吲哚及其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物和这些组合物在治疗由NMDA拮抗剂,乙酰胆碱酯酶抑制剂,5-HT6拮抗剂,其它神经保护剂,抗组胺剂和延缓衰老的药剂有益治疗的疾病和病症的方法中的用途。 相关病理和病情。

    QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
    25.
    发明申请
    QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT 审中-公开
    喹诺酮衍生物和治疗方法

    公开(公告)号:US20090269354A1

    公开(公告)日:2009-10-29

    申请号:US12413510

    申请日:2009-03-27

    CPC分类号: C07D239/94

    摘要: This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.

    摘要翻译: 本发明涉及新的喹唑啉衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物以及这些组合物在治疗通过抑制细胞表面酪氨酸受体激酶有益治疗的疾病和病症的方法中的用途。

    Deuterated 2-amino-3-hydroxypropanoic acid derivatives
    26.
    发明授权
    Deuterated 2-amino-3-hydroxypropanoic acid derivatives 有权
    氘代2-氨基-3-羟基丙酸衍生物

    公开(公告)号:US08704001B2

    公开(公告)日:2014-04-22

    申请号:US13119318

    申请日:2009-09-15

    申请人: Craig E. Masse

    发明人: Craig E. Masse

    IPC分类号: C07C233/05 A61K31/16

    摘要: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.

    摘要翻译: 本发明涉及新的2-氨基-3-羟基丙酸衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用NMDA甘氨酸位点拮抗剂有益治疗的疾病和病症的方法中的用途。

    PYRIMIDINE DERIVATIVES
    28.
    发明申请
    PYRIMIDINE DERIVATIVES 审中-公开
    吡嗪衍生物

    公开(公告)号:US20140018379A1

    公开(公告)日:2014-01-16

    申请号:US13579528

    申请日:2011-02-18

    IPC分类号: C07D239/48

    CPC分类号: C07D239/48 C07B59/002

    摘要: The present invention provides a compound of Formula I or Formula VI: as defined herein. The invention is also directed to compositions comprising the compound of Formula I or Formula VI and methods of therapeutic treatment using the compound of Formula I or Formula VI.

    摘要翻译: 本发明提供式I或式VI化合物:如本文所定义。 本发明还涉及包含式I或式VI化合物的组合物和使用式I或式VI化合物的治疗性治疗方法。

    Tetrahydronaphthalene derivatives
    29.
    发明授权

    公开(公告)号:US08575361B2

    公开(公告)日:2013-11-05

    申请号:US13227047

    申请日:2011-09-07

    IPC分类号: A61K31/4184 C07D235/16

    摘要: This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.